Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss-Reference-Cited by-同舟云学术

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

Published:2023-11-14 Issue:18 Volume:330 Page:1795
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Sodhi Mohit¹,Rezaeianzadeh Ramin¹,Kezouh Abbas²,Etminan Mahyar³

Affiliation:

1. Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

2. StatExpert Ltd, Laval, Quebec, Canada

3. Department of Ophthalmology and Visual Sciences and Medicine, University of British Columbia, Vancouver, Canada

Abstract

This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2810542/jama_sodhi_2023_ld_230072_1703003434.86587.pdf

Reference6 articles.

1. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.;Sauer;Horm Metab Res,2015

2. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial.;Rubino;JAMA,2022

3. Glucagonlike peptide 1–based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.;Singh;JAMA Intern Med,2013

4. Incretin-based drugs and intestinal obstruction: a pharmacovigilance study.;Gudin;Therapie,2020

5. Medication-induced gastroparesis: a case report.;Kalas;J Investig Med High Impact Case Rep,2021

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks;Obesity Pillars;2024-12

2. Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist;Gynecologic Oncology;2024-11

3. Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials;Pharmacological Research;2024-10

4. Endoscopic Management of Weight Regain After Bariatric Surgery;Gastrointestinal Endoscopy Clinics of North America;2024-10

5. Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database;BMC Pharmacology and Toxicology;2024-09-12